DiaMedica Therapeutics Inc. General and Administrative Expense
DiaMedica Therapeutics Inc. (DMAC) reported General and Administrative Expense of $2.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-10
- DiaMedica Therapeutics Inc. general and administrative expense for the quarter ending 2026-06-30 was $2.35M, a 7.32% increase year-over-year.
- DiaMedica Therapeutics Inc. general and administrative expense for the quarter ending 2026-03-31 was $2.50M, a 0.28% increase year-over-year.
- DiaMedica Therapeutics Inc. general and administrative expense for the quarter ending 2025-12-31 was $2.51M, a 28.99% increase year-over-year.
- DiaMedica Therapeutics Inc. general and administrative expense for the quarter ending 2025-09-30 was $2.60M, a 36.63% increase year-over-year.
- DiaMedica Therapeutics Inc. general and administrative expense for fiscal 2025 was $9.78M, a 28.32% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. general and administrative expense for fiscal 2024 was $7.62M, a 6.53% decline from fiscal 2023.
- DiaMedica Therapeutics Inc. general and administrative expense for fiscal 2023 was $8.16M, a 32.38% increase from fiscal 2022.
- DiaMedica Therapeutics Inc. general and administrative expense for fiscal 2022 was $6.16M, a 26.24% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 3 month as first filed | General and Administrative Expense 6 month | General and Administrative Expense 6 month as first filed | General and Administrative Expense 9 month | General and Administrative Expense 9 month as first filed | General and Administrative Expense 12 month | General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.35M 10-Q · filed 2026-08-10 | $4.84M 10-Q · filed 2026-08-10 | $7.35M derived: sum of 3 quarters · filed 2026-08-10 | $9.95M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $2.50M 10-Q · filed 2026-05-06 | $5.01M derived: sum of 2 quarters · filed 2026-05-06 | $7.61M derived: sum of 3 quarters · filed 2026-05-06 | $9.79M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.11M derived: sum of 2 quarters · filed 2026-03-30 | $7.29M derived: sum of 3 quarters · filed 2026-08-10 | $9.78M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-12 | $4.78M derived: sum of 2 quarters · filed 2026-08-10 | $7.27M 10-Q · filed 2025-11-12 | $9.22M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-06-30 | $2.19M 10-Q · filed 2026-08-10 | $4.67M 10-Q · filed 2026-08-10 | $6.62M derived: sum of 3 quarters · filed 2026-08-10 | $8.52M derived: sum of 4 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $2.49M 10-Q · filed 2026-05-06 | $4.44M derived: sum of 2 quarters · filed 2026-05-06 | $6.34M derived: sum of 3 quarters · filed 2026-05-06 | $8.05M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.85M derived: sum of 2 quarters · filed 2026-03-30 | $5.56M derived: sum of 3 quarters · filed 2026-03-30 | $7.62M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-12 | $3.61M derived: sum of 2 quarters · filed 2025-11-12 | $5.67M 10-Q · filed 2025-11-12 | $7.85M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $1.71M 10-Q · filed 2025-08-12 | $3.77M 10-Q · filed 2025-08-12 | $5.95M derived: sum of 3 quarters · filed 2025-08-12 | $7.83M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $2.06M 10-Q · filed 2025-05-13 | $4.24M derived: sum of 2 quarters · filed 2025-05-13 | $6.12M derived: sum of 3 quarters · filed 2025-05-13 | $8.32M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.06M derived: sum of 2 quarters · filed 2025-03-17 | $6.25M derived: sum of 3 quarters · filed 2025-03-17 | $8.16M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $1.89M 10-Q · filed 2024-11-13 | $4.08M derived: sum of 2 quarters · filed 2024-11-13 | $5.99M 10-Q · filed 2024-11-13 | $7.69M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $2.20M 10-Q · filed 2024-08-07 | $4.10M 10-Q · filed 2024-08-07 | $5.80M derived: sum of 3 quarters · filed 2024-08-07 | $7.29M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $1.90M 10-Q · filed 2024-05-08 | $3.61M derived: sum of 2 quarters · filed 2024-05-08 | $5.09M derived: sum of 3 quarters · filed 2024-05-08 | $6.50M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $3.19M derived: sum of 2 quarters · filed 2024-03-19 | $4.60M derived: sum of 3 quarters · filed 2024-03-19 | $6.16M 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | $1.49M 10-Q · filed 2023-11-13 | $2.90M derived: sum of 2 quarters · filed 2023-11-13 | $4.46M 10-Q · filed 2023-11-13 | $5.83M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $1.41M 10-Q · filed 2023-08-14 | $2.97M 10-Q · filed 2023-08-14 | $4.35M derived: sum of 3 quarters · filed 2023-08-14 | $5.43M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $1.56M 10-Q · filed 2023-05-15 | $2.94M derived: sum of 2 quarters · filed 2023-05-15 | $4.02M derived: sum of 3 quarters · filed 2023-05-15 | $5.23M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $2.46M derived: sum of 2 quarters · filed 2023-03-28 | $3.67M derived: sum of 3 quarters · filed 2023-03-28 | $4.88M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | $1.08M 10-Q · filed 2022-11-09 | $2.29M derived: sum of 2 quarters · filed 2022-11-09 | $3.51M 10-Q · filed 2022-11-09 | $4.68M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $1.21M 10-Q · filed 2022-08-11 | $2.42M 10-Q · filed 2022-08-11 | $3.59M derived: sum of 3 quarters · filed 2022-08-11 | $4.75M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-04 | $2.38M derived: sum of 2 quarters · filed 2022-05-04 | $3.54M derived: sum of 3 quarters · filed 2022-05-04 | $4.65M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $2.33M derived: sum of 2 quarters · filed 2022-03-14 | $3.44M derived: sum of 3 quarters · filed 2022-03-14 | $4.49M 10-K · filed 2022-03-14 | $4.39M 10-K · filed 2021-03-10 | |||
| 2020-09-30 | $1.16M 10-Q · filed 2021-11-10 | $1.14M 10-Q · filed 2020-11-04 | $2.27M derived: sum of 2 quarters · filed 2021-11-10 | $3.32M 10-Q · filed 2021-11-10 | $3.24M 10-Q · filed 2020-11-04 | $4.29M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $1.11M 10-Q · filed 2021-08-11 | $1.08M 10-Q · filed 2020-08-11 | $2.16M 10-Q · filed 2021-08-11 | $2.10M 10-Q · filed 2020-08-11 | $3.13M derived: sum of 3 quarters · filed 2021-08-11 | $4.17M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $1.05M 10-Q · filed 2021-05-05 | $1.02M 10-Q · filed 2020-05-13 | $2.02M derived: sum of 2 quarters · filed 2021-05-05 | $3.07M derived: sum of 3 quarters · filed 2021-05-05 | $3.93M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $968.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $2.01M derived: sum of 2 quarters · filed 2021-03-10 | $2.88M derived: sum of 3 quarters · filed 2021-03-10 | $3.69M 10-K · filed 2021-03-10 | ||||
| 2019-09-30 | $1.04M 10-Q · filed 2020-11-04 | $1.91M derived: sum of 2 quarters · filed 2020-11-04 | $2.73M 10-Q · filed 2020-11-04 | $3.39M derived: sum of 4 quarters · filed 2020-11-04 | ||||
| 2019-06-30 | $867.00K 10-Q · filed 2020-08-11 | $1.68M 10-Q · filed 2020-08-11 | $2.35M derived: sum of 3 quarters · filed 2020-08-11 | $3.12M derived: sum of 4 quarters · filed 2020-08-11 | ||||
| 2019-03-31 | $814.00K 10-Q · filed 2020-05-13 | $1.48M derived: sum of 2 quarters · filed 2020-05-13 | $2.26M derived: sum of 3 quarters · filed 2020-05-13 | $3.04M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $666.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $1.44M derived: sum of 2 quarters · filed 2020-03-23 | $2.22M derived: sum of 3 quarters · filed 2020-03-23 | $2.74M 10-K · filed 2020-03-23 | ||||
| 2018-09-30 | $777.00K 10-Q · filed 2019-11-13 | $1.56M derived: sum of 2 quarters · filed 2019-11-13 | $2.07M 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $780.00K 10-Q · filed 2019-08-13 | $1.29M 10-Q · filed 2019-08-13 | ||||||
| 2018-03-31 | $515.00K 10-Q · filed 2019-05-13 | |||||||
| 2017-12-31 | $1.31M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |